ACADIA HEALTHCARE ANNOUNCES THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026
ACADIA HEALTHCARE ANNOUNCES THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE FRANKLIN, Tenn. (November 4, 2026) – Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Results
● Revenue totaled $895.3 million, an increase of 5.1% compared with the third quarter of 2025
Same-facility revenue increased 5.2% compared with the third quarter of ● 2025, as patient days increased 1.1% and revenue per patient day increased 4.0%
Net income attributable to Acadia totaled $34.5 million, or $0.38 per ● diluted share, compared with $36.2 million, or $0.40 per diluted share, in the prior-year period
Adjusted net income attributable to Acadia totaled $54.6 million, or ● $0.60 per diluted share, compared with $64.8 million, or $0.72 per diluted share, in the prior-year period
● Adjusted EBITDA was $176.4 million, compared with $173.0 million in the prior-year period
● Operating cash flows were $97.9 million and capital expenditures were $50.7 million
● Added 220 licensed beds during the third quarter, including 144 beds at a new facility and 76 beds at existing facilities
Adjusted net income attributable to Acadia, Adjusted EBITDA and Adjusted earnings per diluted share are non-GAAP financial measures. A reconciliation of all non-GAAP financial measures in this press release begins on page 9.
“Acadia delivered strong results in the third quarter, and our positive momentum is driving our increased full-year guidance. We remain focused on our key priorities, including expanding access to quality patient care and consistent operational execution with financial discipline," said Debbie Osteen, Chief Executive Officer of Acadia. "We've expanded our footprint by opening 16 new acute facilities over the last four years, and based on the progress we've made so far this year, we now expect to deliver approximately $60 million of incremental EBITDA from these facilities in 2027 relative to 2026. Overall, we are confident that we have the capabilities in place to continue to drive Acadia forward and deliver additional value for our patients, our partners, and our investors.”
Total revenue in the third quarter was $895.3 million, which was an increase of 5.1% compared with the prior-year period. Facilities closed over the last twelve months represented a negative 1.3% impact to reported revenue growth in the quarter.
Same-facility revenue increased 5.2% compared with the prior-year period. Same- facility patient days increased 1.1%, and same-facility revenue per patient day increased 4.0%.
Acute inpatient psychiatric facility (“Acute”) revenue was $524.8 million, which was an increase of 11.3% compared with the prior-year period. Third quarter Acute inpatient volumes increased 7.5% compared with the prior-year period, driven primarily by expanded capacity from both newly constructed and existing facilities.
Specialty treatment facility (“Specialty”) revenue was $136.0 million, a decrease of 8.2% compared with the prior-year period. The revenue decline was related to Specialty facilities in Pennsylvania and the impact from having closed several Specialty facilities over the last 12 months.
Comprehensive treatment center (“CTC”) revenue was $141.1 million, which was a decrease of 2.3% compared with the prior-year period. Residential treatment center (“RTC”) revenue was $93.4 million, an increase of 6.7% compared with the prior-year period.
Total operating expenses were $728.1 million in the third quarter of 2026, an increase of 6.4% compared with the prior-year period.
Salaries, wages and benefits were $490.3 million for the third quarter of 2026, an increase of 6.1% compared with the prior-year period. The increase is primarily due to new facility openings, as well as routine annual wage increases. Same-facility salaries, wages and benefits increased by 4.3%.
Adjusted EBITDA for the third quarter was $176.4 million, compared with $173.0 million in the prior-year period. Third quarter 2026 Adjusted EBITDA includes a favorable pre-tax benefit related to an accrual for expected payments from the Florida supplemental payment program year ended September 30, 2026, which was $13.4 million compared to $5.6 million included in the Company's previous guidance.
The Company added 220 licensed beds during the third quarter, including a 144-bed de novo facility near Jacksonville, Florida and 76 beds added to existing facilities. Additionally, the Company opened one new CTC location and closed one existing CTC location during the quarter.
As of September 30, 2026, the Company had $163.3 million in cash and cash equivalents and $710.1 million available under its $1.0 billion revolving credit facility. As of September 30, 2026, Acadia’s net leverage ratio was 3.9x Adjusted EBITDA, calculated in accordance with its Credit Agreement as disclosed in the Company’s latest periodic reports and other filings with the Securities and Exchange Commission (“SEC”). - MORE - ACHC Announces Third Quarter 2026 Results
Full Year 2026November Full Year 2026July Guidance Range Guidance Range Revenue $3.44 to $3.46 billion $3.40 to $3.45 billion Adjusted EBITDA $615 to $625 million $590 to $615 million Adjusted earnings per $1.70 to $1.80 $1.45 to $1.60 diluted share Operating Cash Flow $375 to $400 million $350 to $400 million Capital expenditures $210 to $230 million $235 to $255 million
The Company’s guidance does not include the impact of any future acquisitions, divestitures, transaction, legal and other costs or non-recurring legal settlements expense. Conference Call Acadia will hold a conference call to discuss its third quarter financial results at 8:00 a.m. Central Time / 9:00 a.m. Eastern Time on Thursday, November 5, 2026. A live webcast of the conference call will be available at in the “Investors” section of the website. The archived webcast will be available after the call has ended. About Acadia Acadia Healthcare is the largest stand-alone behavioral healthcare company in the United States, providing mental health and addiction treatment services across a comprehensive continuum of care that includes inpatient psychiatric hospitals, specialty treatment facilities, RTCs, and outpatient clinics. Acadia operates 280 behavioral health facilities across 40 states and Puerto Rico and serves more than 85,000 patients daily. Guided by its mission, Acadia provides paths to healing through evidence-based treatment and compassionate care that inspires hope, improves lives and elevates communities. Description of Business Unless the context otherwise requires, all references herein to “Acadia,” “Acadia Healthcare,” “the Company,” “we,” “us” or “our” mean Acadia Healthcare Company, Inc. and its consolidated subsidiaries. Acadia Healthcare Company, Inc. is a holding company whose direct and indirect subsidiaries conduct healthcare and management operations. The terms “facilities,” “centers,” “clinics,” and “hospitals” refer to entities owned, operated, or managed by subsidiaries of Acadia Healthcare Company, Inc. References herein to “employees” refer to employees of subsidiaries of Acadia Healthcare Company, Inc. - MORE - ACHC Announces Third Quarter 2026 Results
Forward-Looking Information This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements related to our strategy, growth and anticipated operating results for future periods. Generally, words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue” and “believe” or the negative of or other variation on these and other similar expressions identify forward- looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise any forward- looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties, and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of facility expansions, acquisitions, joint ventures and de novo transactions; (ii) Acadia’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions or delays in payments received by Acadia from government, commercial and other third-party payors or denials of claims for payment, including, without limitation, because of the significant changes to Medicaid financing mechanisms introduced by the One Big Beautiful Bill Act (the “OBBBA”) enacted on July 4, 2025; (iv) the occurrence of patient incidents, governmental investigations, litigation and adverse regulatory actions, which could adversely affect the price of our common stock and result in substantial payments and incremental regulatory burdens; (v) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (vi) changes in expectations resulting from actuarial and other reviews of Acadia’s liability reserves and other aspects of its business; (vii) potential disruptions to our information technology systems or adverse impacts of a cybersecurity incident; and (viii) potential operating difficulties, including, without limitation, disruption to the U.S. economy and financial markets; reduced admissions and patient volumes, including, without limitation, due to the OBBBA’s introduction of work or community engagement requirements in the Medicaid expansion population; increased costs relating to labor, supply chain and other expenditures; changes in competition and client preferences; and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategies. These factors and others are more fully described in Acadia’s periodic reports and other filings with the SEC. - MORE - ACHC Announces Third Quarter 2026 Results
Accounts (60,781 ) (64,958 ) receivable, net Other current 43,992 (17,590 ) assets Other assets (1,976 ) (10,865 ) Accounts payable and other accrued 36,311 33,584 liabilities Accrued salaries (10,138 ) 5,158 and benefits Other liabilities 35,426 12,554 Net cash provided by operating 321,481 218,191 activities Investing activities: Cash paid for acquisitions, net — (8,165 ) of cash acquired Cash paid for capital (165,860 ) (478,617 ) expenditures Proceeds from sale of property and 33,901 23,151 equipment Other (3,439 ) (145 ) Net cash used in investing (135,398 ) (463,776 ) activities Financing activities: Borrowings on — 1,200,000 long-term debt Borrowings on revolving credit 85,000 875,000 facility Principal payments on revolving (215,000 ) (1,035,000 ) credit facility Principal payments (20,313 ) (8,125 ) on long-term debt Repayment of — (670,856 ) long-term debt Payment of debt — (18,615 ) issuance costs Repurchase of shares for payroll tax withholding, net (4,150 ) (3,953 ) of proceeds from stock option exercises Repurchase of — (50,034 ) common stock Contributions from noncontrolling 2,759 5,000 partners in joint ventures Distributions to noncontrolling (4,207 ) (3,877 ) partners in joint ventures Cash paid for contingent — (1,500 ) consideration Other (107 ) (67 ) Net cash (used in) provided by (156,018 ) 287,973 financing activities Net increase in cash and cash 30,065 42,388 equivalents Cash and cash equivalents at 133,242 76,305 beginning of the period Cash and cash equivalents at end $ 163,307 $ 118,693 of the period Effect of acquisitions: Assets acquired, $ 33,591 $ 36,715 excluding cash Liabilities — (1,193 ) assumed Redeemable noncontrolling interest (33,591 ) (27,357 ) resulting from an acquisition Cash paid for acquisitions, net $ — $ 8,165 of cash acquired
(1)Total facility and same facility results may not be indicative of the overall performance of our business and should not be considered as alternatives for net income or any other performance measures in accordance with GAAP (as defined herein).
(2)Same facility results for the periods presented include facilities we have operated for more than one year and exclude certain closed services.
(3)Average length of stay is defined as patient days divided by admissions. - MORE - ACHC Announces Third Quarter 2026 Results
Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted EBITDA and Same Facility Adjusted EBITDA
See footnotes on pages 13-14. - MORE - ACHC Announces Third Quarter 2026 Results
Footnotes We have included certain financial measures in this press release, including those listed below, which are “non-GAAP financial measures” as defined under the rules and regulations promulgated by the SEC. These non-GAAP financial measures include, and are defined, as follows:
• EBITDA: net income attributable to Acadia Healthcare Company, Inc. adjusted for net income attributable to noncontrolling interests, provision for income taxes, net interest expense and depreciation and amortization.
• Adjusted EBITDA: EBITDA adjusted for equity-based compensation expense, transaction, legal and other costs, debt extinguishment costs, legal settlements expense, loss on impairment and gain on sale of property, net.
• Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc.: net income attributable to Acadia Healthcare Company, Inc. adjusted for transaction, legal and other costs, debt extinguishment costs, legal settlements expense, loss on impairment, gain on sale of property, net, and provision for income taxes.
• Adjusted income attributable to Acadia Healthcare Company, Inc.: Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc. adjusted for the income tax effect of adjustments to income.
• Total facility adjusted EBITDA: Adjusted EBITDA adjusted for general and administrative costs related to our corporate functions. General and administrative costs directly related to the facilities are included in total facility results.
• Same facility adjusted EBITDA: Adjusted EBITDA for facilities and services to those facilities operated in both the current and prior year. These metrics exclude the operating results associated with facilities under operation for less than one year and facilities acquired, divested or removed from service during the current or prior year.
The non-GAAP financial measures presented herein are supplemental measures of our performance and are not required by, or presented in accordance with, generally accepted accounting principles in the United States (“GAAP”). The non- GAAP financial measures presented herein are not measures of our financial performance under GAAP and should not be considered as alternatives to net income or any other performance measures derived in accordance with GAAP or as an alternative to cash flow from operating activities as measures of our liquidity. Our measurements of these non-GAAP financial measures may not be comparable to similarly titled measures of other companies. We have included information concerning the non-GAAP financial measures in this press release because we believe that such information is used by certain investors as measures of a company’s historical performance. We believe these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of issuers of equity securities, many of which present similar non-GAAP financial measures when reporting their results. Because the non-GAAP financial measures are not measurements determined in accordance with GAAP and are thus susceptible to varying calculations, the non-GAAP financial measures, as presented, may not be comparable to other similarly titled measures of other companies. Our presentation of these non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items. - MORE - ACHC Announces Third Quarter 2026 Results
November 4, 2026 Total facility results include operating results for all of our facilities and services but exclude general and administrative costs related to our corporate functions. Such costs related to our corporate functions include, amongst others, costs for accounting and finance, information systems, human resources, legal and operational and executive leadership. General and administrative costs directly related to the facilities are included in facility results. Such costs directly related to our facilities include, amongst others, labor at the facility level, insurance, including property, professional, legal and general liability insurance, hospital supplies, including medication, utilities and food service, and general maintenance costs for the facility. We determine which general and administrative costs to exclude and include in total facility results by ensuring those costs directly associated with facility operations are captured at the facility level for reporting. Note that total facility costs include those related to new facilities and the cost of closure and run-out costs related to facilities we have closed. We believe that providing results on a total facility basis is helpful to our investors as a measure of our financial and operating performance because it neutralizes the impact of corporate-level items that do not arise out of our core operations at our facilities.
Same facility results include operating results only for facilities and services operated in both the current and prior year. These metrics exclude the operating results associated with facilities under operation for less than one year and facilities acquired during the current or prior year, as well as facilities divested or removed from service. We believe that providing results on a same facility basis is helpful to investors because it neutralizes the impact of new facilities that are in early stages of operation and facilities that we no longer operate, each of which may distort investors’ understanding of the Company’s underlying performance at our existing and continuing facilities. Further, we believe that providing same facility information is helpful to our investors as a measure of the financial and operating performance of our existing and continuing facilities on a comparable basis, and same facility results provide investors with information useful in understanding underlying organic growth in such facilities. For these reasons, we believe that same facility results are particularly useful during periods of significant expansion or contraction.
Total facility results reflect adjustments that are intended to provide the specific presentation described above, and same facility results reflect adjustments that may be irregular in timing from period to period related to newly opened or acquired facilities or facilities that we no longer operate, and may omit certain results that investors may view as important. Total facility and same facility results may therefore not be indicative of the overall performance of our business and should be not be considered as alternatives for net income or any other performance measures derived in accordance with GAAP.
The Company is not able to provide a reconciliation of projected Adjusted EBITDA and adjusted earnings per diluted share, where provided, to expected results due to the unknown effect, timing and potential significance of transaction-related expenses and the tax effect of such expenses. - MORE - ACHC Announces Third Quarter 2026 Results
Footnotes (continued) (a) Represents the equity-based compensation expense of Acadia. Equity-based compensation expense is excluded from Adjusted EBITDA because we believe that the cost of equity awards granted to employees does not contribute to the earnings potentially available for distributions to Acadia's equity holders or reinvestment into the Company's business.
(b) Represents transaction, legal, and other costs incurred by Acadia primarily related to the following categories: (1) government investigations; (2) legal, accounting, and other acquisition-related costs; (3) termination and restructuring costs; and (4) management transition costs. Government investigations include legal fees and settlement costs related to certain litigation. Legal, accounting and other acquisition-related costs include costs incurred for the development of new facilities ($0.1 million and $0.5 million for the three months ended September 30, 2026 and 2025, respectively, and $0.5 million and $1.9 million for the nine months ended September 30, 2026 and 2025, respectively); and legal and settlement costs incurred related to certain litigation not included in government investigations ($3.2 million and $0.4 million for the three months ended September 30, 2026 and 2025, respectively, and $12.9 million and $(2.3) million for the nine months ended September 30, 2026 and 2025, respectively). Termination and restructuring costs include costs, net of gains, incurred related to workforce reductions, contract amendments, and the closure and disposition of certain facilities, including related lease terminations. Management transition costs consist primarily of severance benefits incurred with the departure of the Company’s former Chief Executive Officer, Christopher H. Hunter. The table below quantifies each of the components of transaction, legal and other costs for the periods presented. Such transaction, legal and other costs are excluded from Adjusted EBITDA because we believe that the nature, size, and number of these costs can vary dramatically from period to period and between Acadia and its peers and can also obscure underlying business trends and make comparisons of long-term performance difficult.
(c) Represents debt extinguishment costs recorded during the first quarter of 2025 in connection with the refinancing of the prior credit facility. Debt extinguishment is excluded from Adjusted EBITDA because we believe that this expense is unrelated to Acadia’s day-to-day business operations and not indicative of Acadia’s ongoing operating results.
(d) Legal settlements gain for the three months ended September 30, 2026 primarily related to the receipt of insurance proceeds in excess of payment of attorneys' fees and expenses to plaintiffs' counsel in connection with the settlement of derivative cases against the Company. Legal settlements expense for the nine months ended September 30, 2026, relates to costs associated with the settlement of Sandoval v. Acadia Healthcare Company, Inc., Marin County Super. Ct. No. CIV1802171,partially offset by the receipt of insurance proceeds in excess of payment of attorneys' fees and expenses to plaintiffs' counsel in connection with the settlement of derivative cases against the Company. Legal settlements expense for the nine months ended September 30, 2025, relates to costs associated with the Desert Hills litigation. Legal settlements expense is excluded from Adjusted EBITDA because we believe that this expense is unrelated to Acadia’s day-to-day business operations and not indicative of Acadia’s ongoing operating results.
(e) Represents non-cash impairment charges. Non-cash impairment charges are excluded from Adjusted EBITDA because we believe that these charges are unrelated to Acadia’s day-to-day business operations and not indicative of Acadia’s ongoing operating results. - MORE - ACHC Announces Third Quarter 2026 Results
November 4, 2026 (f) Represents loss (gain) on facility property sales. Net gains from facility property sales are excluded from Adjusted EBITDA because we believe that these gains are unrelated to Acadia’s day-to-day business operations and not indicative of Acadia’s ongoing operating results.
(g) Represents general and administrative costs related to our corporate functions, including, amongst others, costs for accounting and finance, information systems, human resources, legal and operational and executive leadership. We determine which general and administrative costs to exclude and include in total facility results by ensuring those costs directly associated with facility operations are captured at the facility level for reporting. Corporate general and administrative costs are excluded to present Total Facility Adjusted EBITDA because we believe that providing results on a total facility basis is helpful to our investors as a measure of the financial and operating performance of our core operations at our facilities.
(h) Represents the portion of EBITDA for the periods presented attributable to de novos and acquired facilities in operation for less than one year and facilities closed during such period. De novos are newly developed facilities built by Acadia or with a joint venture partner. Such amounts are excluded from Adjusted EBITDA to present Same Facility Adjusted EBITDA because we believe providing same facility information is helpful to our investors as a measure of the financial and operating performance of our existing and continuing facilities on a comparable basis, and same facility results provide investors with information useful in understanding underlying organic growth in such facilities.
(i) Represents the income tax effect of adjustments to income based on tax rates of 24.8% and 19.8% for the three months ended September 30, 2026 and 2025, respectively, and 25.9% and 22.8% for the nine months ended September 30, 2026 and 2025, respectively. We believe excluding the income tax effect of adjustments to income assists investors in understanding the tax provision associated with those adjustments and the effect on net income. Investor Contact: - MORE -
Full text with the tables
Exhibit 99.1
ACADIA HEALTHCARE ANNOUNCES THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026
FINANCIAL GUIDANCE
FRANKLIN, Tenn. (November 4, 2026) – Acadia Healthcare Company, Inc. (“Acadia”
or the “Company”) (NASDAQ: ACHC) today announced financial results for the third
quarter ended September 30, 2026.
Third Quarter 2026 Results
● Revenue totaled $895.3 million, an increase of 5.1% compared with the
third quarter of 2025
Same-facility revenue increased 5.2% compared with the third quarter of
● 2025, as patient days increased 1.1% and revenue per patient day
increased 4.0%
Net income attributable to Acadia totaled $34.5 million, or $0.38 per
● diluted share, compared with $36.2 million, or $0.40 per diluted share,
in the prior-year period
Adjusted net income attributable to Acadia totaled $54.6 million, or
● $0.60 per diluted share, compared with $64.8 million, or $0.72 per
diluted share, in the prior-year period
● Adjusted EBITDA was $176.4 million, compared with $173.0 million in the
prior-year period
● Operating cash flows were $97.9 million and capital expenditures were
$50.7 million
● Added 220 licensed beds during the third quarter, including 144 beds at a
new facility and 76 beds at existing facilities
Adjusted net income attributable to Acadia, Adjusted EBITDA and Adjusted
earnings per diluted share are non-GAAP financial measures. A reconciliation of
all non-GAAP financial measures in this press release begins on page 9.
“Acadia delivered strong results in the third quarter, and our positive momentum
is driving our increased full-year guidance. We remain focused on our key
priorities, including expanding access to quality patient care and consistent
operational execution with financial discipline," said Debbie Osteen, Chief
Executive Officer of Acadia. "We've expanded our footprint by opening 16 new
acute facilities over the last four years, and based on the progress we've made
so far this year, we now expect to deliver approximately $60 million of
incremental EBITDA from these facilities in 2027 relative to 2026. Overall, we
are confident that we have the capabilities in place to continue to drive Acadia
forward and deliver additional value for our patients, our partners, and our
investors.”
Third Quarter
Financial Summary
(dollars in
millions, except
per share amounts) 2026 2025 Change (%)
──────────────────────────────────────────────────────────────────────────────
Acute Inpatient
Psychiatric $ 524.8 $ 471.5 11 %
Facilities
Specialty Treatment $ 136.0 $ 148.1 (8 %)
Facilities
Comprehensive $ 141.1 $ 144.5 (2 %)
Treatment Centers
Residential $ 93.4 $ 87.5 7 %
Treatment Centers
Total Revenue $ 895.3 $ 851.6 5 %
Reported Net Income $ 34.5 $ 36.2 (5 %)
Adjusted EBITDA $ 176.4 $ 173.0 2 %
Reported EPS $ 0.38 $ 0.40 (5 %)
Adjusted EPS $ 0.60 $ 0.72 (17 %)
- MORE -
ACHC Announces Third Quarter 2026 Results
Page 2
November 4, 2026
Discussion of Third Quarter Results
Total revenue in the third quarter was $895.3 million, which was an increase of
5.1% compared with the prior-year period. Facilities closed over the last twelve
months represented a negative 1.3% impact to reported revenue growth in the
quarter.
Same-facility revenue increased 5.2% compared with the prior-year period. Same-
facility patient days increased 1.1%, and same-facility revenue per patient day
increased 4.0%.
Acute inpatient psychiatric facility (“Acute”) revenue was $524.8 million, which
was an increase of 11.3% compared with the prior-year period. Third quarter
Acute inpatient volumes increased 7.5% compared with the prior-year period,
driven primarily by expanded capacity from both newly constructed and existing
facilities.
Specialty treatment facility (“Specialty”) revenue was $136.0 million, a
decrease of 8.2% compared with the prior-year period. The revenue decline was
related to Specialty facilities in Pennsylvania and the impact from having
closed several Specialty facilities over the last 12 months.
Comprehensive treatment center (“CTC”) revenue was $141.1 million, which was a
decrease of 2.3% compared with the prior-year period. Residential treatment
center (“RTC”) revenue was $93.4 million, an increase of 6.7% compared with the
prior-year period.
Total operating expenses were $728.1 million in the third quarter of 2026, an
increase of 6.4% compared with the prior-year period.
Salaries, wages and benefits were $490.3 million for the third quarter of 2026,
an increase of 6.1% compared with the prior-year period. The increase is
primarily due to new facility openings, as well as routine annual wage
increases. Same-facility salaries, wages and benefits increased by 4.3%.
Adjusted EBITDA for the third quarter was $176.4 million, compared with $173.0
million in the prior-year period. Third quarter 2026 Adjusted EBITDA includes a
favorable pre-tax benefit related to an accrual for expected payments from the
Florida supplemental payment program year ended September 30, 2026, which was
$13.4 million compared to $5.6 million included in the Company's previous
guidance.
Development Activity
The Company added 220 licensed beds during the third quarter, including a
144-bed de novo facility near Jacksonville, Florida and 76 beds added to
existing facilities. Additionally, the Company opened one new CTC location and
closed one existing CTC location during the quarter.
Cash and Liquidity
As of September 30, 2026, the Company had $163.3 million in cash and cash
equivalents and $710.1 million available under its $1.0 billion revolving credit
facility. As of September 30, 2026, Acadia’s net leverage ratio was 3.9x
Adjusted EBITDA, calculated in accordance with its Credit Agreement as disclosed
in the Company’s latest periodic reports and other filings with the Securities
and Exchange Commission (“SEC”).
- MORE -
ACHC Announces Third Quarter 2026 Results
Page 3
November 4, 2026
2026 Financial Guidance
Acadia today updated its financial guidance for 2026, as follows:
Full Year 2026November Full Year 2026July
Guidance Range Guidance Range
Revenue $3.44 to $3.46 billion $3.40 to $3.45 billion
Adjusted EBITDA $615 to $625 million $590 to $615 million
Adjusted earnings per $1.70 to $1.80 $1.45 to $1.60
diluted share
Operating Cash Flow $375 to $400 million $350 to $400 million
Capital expenditures $210 to $230 million $235 to $255 million
The Company’s guidance does not include the impact of any future acquisitions,
divestitures, transaction, legal and other costs or non-recurring legal
settlements expense.
Conference Call
Acadia will hold a conference call to discuss its third quarter financial
results at 8:00 a.m. Central Time / 9:00 a.m. Eastern Time on Thursday, November
5, 2026. A live webcast of the conference call will be available at in the
“Investors” section of the website. The archived webcast will be available after
the call has ended.
About Acadia
Acadia Healthcare is the largest stand-alone behavioral healthcare company in
the United States, providing mental health and addiction treatment services
across a comprehensive continuum of care that includes inpatient psychiatric
hospitals, specialty treatment facilities, RTCs, and outpatient clinics. Acadia
operates 280 behavioral health facilities across 40 states and Puerto Rico and
serves more than 85,000 patients daily. Guided by its mission, Acadia provides
paths to healing through evidence-based treatment and compassionate care that
inspires hope, improves lives and elevates communities.
Description of Business
Unless the context otherwise requires, all references herein to “Acadia,”
“Acadia Healthcare,” “the Company,” “we,” “us” or “our” mean Acadia Healthcare
Company, Inc. and its consolidated subsidiaries. Acadia Healthcare Company, Inc.
is a holding company whose direct and indirect subsidiaries conduct healthcare
and management operations. The terms “facilities,” “centers,” “clinics,” and
“hospitals” refer to entities owned, operated, or managed by subsidiaries of
Acadia Healthcare Company, Inc. References herein to “employees” refer to
employees of subsidiaries of Acadia Healthcare Company, Inc.
- MORE -
ACHC Announces Third Quarter 2026 Results
Page 4
November 4, 2026
Forward-Looking Information
This press release contains “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, including statements related to our
strategy, growth and anticipated operating results for future periods.
Generally, words such as “may,” “will,” “should,” “could,” “anticipate,”
“expect,” “intend,” “estimate,” “plan,” “continue” and “believe” or the negative
of or other variation on these and other similar expressions identify forward-
looking statements. These forward-looking statements are made only as of the
date of this press release. We do not undertake to update or revise any forward-
looking statements, whether as a result of new information, future events or
otherwise. Forward-looking statements are based on current expectations and
involve risks and uncertainties, and our future results could differ
significantly from those expressed or implied by our forward-looking statements.
Factors that may cause actual results to differ materially include, without
limitation, (i) potential difficulties in successfully integrating the
operations of acquired facilities or realizing the expected benefits and
synergies of facility expansions, acquisitions, joint ventures and de novo
transactions; (ii) Acadia’s ability to add beds, expand services, enhance
marketing programs and improve efficiencies at its facilities; (iii) potential
reductions or delays in payments received by Acadia from government, commercial
and other third-party payors or denials of claims for payment, including,
without limitation, because of the significant changes to Medicaid financing
mechanisms introduced by the One Big Beautiful Bill Act (the “OBBBA”) enacted on
July 4, 2025; (iv) the occurrence of patient incidents, governmental
investigations, litigation and adverse regulatory actions, which could adversely
affect the price of our common stock and result in substantial payments and
incremental regulatory burdens; (v) the risk that Acadia may not generate
sufficient cash from operations to service its debt and meet its working capital
and capital expenditure requirements; (vi) changes in expectations resulting
from actuarial and other reviews of Acadia’s liability reserves and other
aspects of its business; (vii) potential disruptions to our information
technology systems or adverse impacts of a cybersecurity incident; and (viii)
potential operating difficulties, including, without limitation, disruption to
the U.S. economy and financial markets; reduced admissions and patient volumes,
including, without limitation, due to the OBBBA’s introduction of work or
community engagement requirements in the Medicaid expansion population;
increased costs relating to labor, supply chain and other expenditures; changes
in competition and client preferences; and general economic or industry
conditions that may prevent Acadia from realizing the expected benefits of its
business strategies. These factors and others are more fully described in
Acadia’s periodic reports and other filings with the SEC.
- MORE -
ACHC Announces Third Quarter 2026 Results
Page 5
November 4, 2026
Acadia Healthcare Company, Inc.
Condensed Consolidated Statements of Income
(Unaudited)
Three
Mont…
Ended
Sept…
30,
2026
(In Nine
thou… Mon…
exce… End…
per Sep…
share 30,
amou… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Rev… $ 895,… $ 851,… $ 2,58… $ 2,4…
Sal…
wag…
and
ben…
(in…
equ…
com…
exp… 490,… 462,… 1,43… 1,3…
of
$9,…
$6,…
$28…
and
$25…
res…
Pro… 58,6… 51,4… 167,… 147…
fees
Sup… 31,5… 30,4… 91,1… 87,…
Ren…
and 11,9… 11,7… 35,5… 36,…
lea…
Oth…
ope… 135,… 128,… 422,… 377…
exp…
Dep…
and 53,1… 47,4… 155,… 143…
amo…
Int…
exp… 37,2… 36,6… 113,… 100…
net
Debt
ext… — — — 1,2…
cos…
Leg…
set… (7,1… ) — 6,600 3,5…
(ga…
exp…
Loss
on 3,546 — 10,9… 1,4…
imp…
Loss
(ga…
on 189 — (3,3… ) (8,… )
sale
of
pro…
Tra…
leg…
and 23,7… 42,9… 68,3… 138…
oth…
cos…
Tot… 838,… 811,… 2,50… 2,3…
exp…
Inc…
bef… 56,4… 39,9… 89,4… 103…
inc…
tax…
Pro…
for 17,8… 1,668 34,0… 18,…
inc…
tax…
Net 38,6… 38,3… 55,3… 85,…
inc…
Net
inc…
att… (4,1… ) (2,0… ) (5,8… ) (10… )
to
non…
int…
Net
inc…
att…
to $ 34,4… $ 36,2… $ 49,5… $ 74,…
Aca…
Hea…
Com…
Inc.
Ear…
per
sha…
att…
to
Aca…
Hea…
Com…
Inc.
sto…
Bas… $ 0.38 $ 0.40 $ 0.55 $ 0.82
Dil… $ 0.38 $ 0.40 $ 0.54 $ 0.82
Wei…
sha…
out…
Bas… 90,8… 90,4… 90,7… 90,…
Dil… 91,7… 90,5… 91,4… 91,…
- MORE -
ACHC Announces Third Quarter 2026 Results
Page 6
November 4, 2026
Acadia Healthcare Company, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
September 30,
2026 December 31,
ASSETS (In thousands) 2025
Current
assets:
──────────────────────────────────────────────────────────────────────────────
Cash and cash $ 163,307 $ 133,242
equivalents
Accounts
receivable, 501,385 440,604
net
Other current 216,624 240,293
assets
Total current 881,316 814,139
assets
Property and 3,048,638 3,111,212
equipment, net
Goodwill 1,315,642 1,296,342
Intangible 100,189 96,672
assets, net
Deferred tax 2,422 2,528
assets
Operating
lease 139,142 134,005
right-of-use
assets
Other assets 67,241 72,550
Total assets $ 5,554,590 $ 5,527,448
LIABILITIES
AND EQUITY
Current
liabilities:
Current
portion of $ 32,500 $ 28,438
long-term debt
Accounts 138,557 150,403
payable
Accrued
salaries and 184,392 188,638
benefits
Current
portion of
operating 21,739 21,160
lease
liabilities
Other accrued 174,842 136,555
liabilities
Total current 552,030 525,194
liabilities
Long-term debt 2,319,859 2,471,529
Deferred tax 93,639 66,605
liabilities
Operating
lease 129,547 121,961
liabilities
Other 207,147 201,607
liabilities
Total 3,302,222 3,386,896
liabilities
Redeemable
noncontrolling 229,876 191,592
interests
Equity:
Common stock 909 905
Additional
paid-in 2,737,905 2,713,896
capital
Accumulated (716,322 ) (765,841 )
deficit
Total equity 2,022,492 1,948,960
Total
liabilities $ 5,554,590 $ 5,527,448
and equity
- MORE -
ACHC Announces Third Quarter 2026 Results
Page 7
November 4, 2026
Acadia Healthcare Company, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Nine Months Ended
September 30,
2026
Operating (In thousands) 2025
activities:
──────────────────────────────────────────────────────────────────────────────
Net income $ 55,374 $ 85,317
Adjustments to
reconcile net
income to
net cash provided
by operating
activities:
Depreciation and 155,987 143,495
amortization
Amortization of
debt issuance 3,796 3,513
costs
Equity-based
compensation 28,192 25,257
expense
Deferred income 27,141 3,309
taxes
Debt
extinguishment — 1,269
costs
Non-cash legal
settlements — 3,504
expense
Loss on impairment 10,910 1,452
Loss (gain) on (3,392 ) (8,715 )
sale of property
Other 639 1,907
Change in
operating assets
and
liabilities, net
of effect of
acquisitions:
Accounts (60,781 ) (64,958 )
receivable, net
Other current 43,992 (17,590 )
assets
Other assets (1,976 ) (10,865 )
Accounts payable
and other accrued 36,311 33,584
liabilities
Accrued salaries (10,138 ) 5,158
and benefits
Other liabilities 35,426 12,554
Net cash provided
by operating 321,481 218,191
activities
Investing
activities:
Cash paid for
acquisitions, net — (8,165 )
of cash
acquired
Cash paid for
capital (165,860 ) (478,617 )
expenditures
Proceeds from sale
of property and 33,901 23,151
equipment
Other (3,439 ) (145 )
Net cash used in
investing (135,398 ) (463,776 )
activities
Financing
activities:
Borrowings on — 1,200,000
long-term debt
Borrowings on
revolving credit 85,000 875,000
facility
Principal payments
on revolving (215,000 ) (1,035,000 )
credit
facility
Principal payments (20,313 ) (8,125 )
on long-term debt
Repayment of — (670,856 )
long-term debt
Payment of debt — (18,615 )
issuance costs
Repurchase of
shares for payroll
tax
withholding, net (4,150 ) (3,953 )
of proceeds from
stock
option exercises
Repurchase of — (50,034 )
common stock
Contributions from
noncontrolling 2,759 5,000
partners in joint
ventures
Distributions to
noncontrolling (4,207 ) (3,877 )
partners
in joint ventures
Cash paid for
contingent — (1,500 )
consideration
Other (107 ) (67 )
Net cash (used in)
provided by (156,018 ) 287,973
financing
activities
Net increase in
cash and cash 30,065 42,388
equivalents
Cash and cash
equivalents at 133,242 76,305
beginning
of the period
Cash and cash
equivalents at end $ 163,307 $ 118,693
of the
period
Effect of
acquisitions:
Assets acquired, $ 33,591 $ 36,715
excluding cash
Liabilities — (1,193 )
assumed
Redeemable
noncontrolling
interest (33,591 ) (27,357 )
resulting from an
acquisition
Cash paid for
acquisitions, net $ — $ 8,165
of cash
acquired
- MORE -
ACHC Announces Third Quarter 2026 Results
Page 8
November 4, 2026
Acadia Healthcare Company, Inc.
Operating Statistics(1)
(Unaudited, $ in thousands except per Patient Day metrics)
T… N…
M… M…
E… E…
… S… S…
… 3… % 3… %
… 2… 2… C… 2… 2… C…
…
──────────────────────────────────────────────────────────────────────────────
… $ 8… $ 8… 5… % $ 2… $ 2… 4.0 %
… 8… 8… 1… % 2… 2… 1.2 %
…
… 5… 5… 6… % 1… 1… 6.5 %
…
…
… 1… 1… -… % 1… 1… -5… %
…
…
…
… $ 1… $ 1… 4… % $ 1… $ 1… 2.8 %
…
…
… $ 2… $ 2… 6… % $ 6… $ 6… -1… %
…
…
…
…
… $ 8… $ 8… 5… % $ 2… $ 2… 4.0 %
… 8… 8… 0… % 2… 2… 0.8 %
…
… 5… 5… 7… % 1… 1… 7.0 %
…
…
… 1… 1… -… % 1… 1… -5… %
…
…
…
… $ 1… $ 1… 4… % $ 1… $ 1… 3.2 %
…
…
… $ 2… $ 2… 2… % $ 5… $ 6… -5… %
…
(1)Total facility and same facility results may not be indicative of the overall
performance of our business and should not be considered as alternatives for net
income or any other performance measures in accordance with GAAP (as defined
herein).
(2)Same facility results for the periods presented include facilities we have
operated for more than one year and exclude certain closed services.
(3)Average length of stay is defined as patient days divided by admissions.
- MORE -
ACHC Announces Third Quarter 2026 Results
Page 9
November 4, 2026
Acadia Healthcare Company, Inc.
Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to
Adjusted EBITDA and
Same Facility Adjusted EBITDA
(Unaudited)
Three
Mont…
Ended Nine
Sept… Mon…
30, End…
2026 Sep…
(in 30,
thou… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net
inc…
att…
to $ 34,4… $ 36,2… $ 49,5… $ 74,…
Aca…
Hea…
Com…
Inc.
Net
inc…
att… 4,164 2,071 5,855 10,…
to
non…
int…
Pro…
for 17,8… 1,668 34,0… 18,…
inc…
tax…
Int…
exp… 37,2… 36,6… 113,… 100…
net
Dep…
and 53,1… 47,4… 155,… 143…
amo…
EBI… 146,… 124,… 359,… 347…
Adj…
Equ…
com… 9,246 6,031 28,1… 25,…
exp…
(a)
Tra…
leg…
and 23,7… 42,9… 68,3… 138…
oth…
cos…
(b)
Debt
ext… — — — 1,2…
cos…
(c)
Leg…
set…
(ga… (7,1… ) — 6,600 3,5…
exp…
(d)
Loss
on 3,546 — 10,9… 1,4…
imp…
(e)
Loss
(ga…
on
sale 189 — (3,3… ) (8,… )
of
pro…
(f)
Adj… $ 176,… $ 173,… $ 469,… $ 509…
EBI…
Cor…
gen…
and (39,… ) (37,… ) (119… ) (11… )
adm…
cos…
(g)
Tot…
Fac… 216,… 210,… 589,… 623…
Adj…
EBI…
De
nov…
acq…
and (12,… ) (4,7… ) (39,… ) (16… )
clo…
fac…
(h)
Same
Fac… $ 228,… $ 215,… $ 629,… $ 639…
Adj…
EBI…
See footnotes on pages 13-14.
Acadia Healthcare Company, Inc.
Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to
Adjusted Income Attributable to Acadia Healthcare Company, Inc.
(Unaudited)
Three
Mont…
Ended
Sept…
30,
2026
(in Nine
thou… Mont…
exce… Ended
per Sept…
share 30,
amou… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net
inc…
att…
to $ 34,4… $ 36,2… $ 49,… $ 74,7…
Aca…
Hea…
Com…
Inc.
Adj…
to
inc…
Tra…
leg…
and 23,7… 42,9… 68,… 138,…
oth…
cos…
(b)
Debt
ext… — — — 1,269
cos…
(c)
Leg…
set…
(ga… (7,1… ) — 6,6… 3,504
exp…
(d)
Loss
on 3,546 — 10,… 1,452
imp…
(e)
Loss
(ga…
on
sale 189 — (3,… ) (8,7… )
of
pro…
(f)
Pro…
for 17,8… 1,668 34,… 18,1…
inc…
tax…
Adj…
inc…
bef…
inc…
tax…
att… 72,6… 80,8… 166… 228,…
to
Aca…
Hea…
Com…
Inc.
Inc…
tax
eff…
of 18,0… 16,0… 43,… 52,2…
adj…
to
inc…
(i)
Adj…
inc…
att…
to 54,6… 64,8… 122… 176,…
Aca…
Hea…
Com…
Inc.
Wei…
sha…
out… 91,7… 90,5… 91,… 91,2…
-
dil…
Adj…
inc…
att…
to
Aca…
Hea… $ 0.60 $ 0.72 $ 1.34 $ 1.94
Com…
Inc.
per
dil…
sha…
See footnotes on pages 13-14.
- MORE -
ACHC Announces Third Quarter 2026 Results
Page 10
November 4, 2026
Acadia Healthcare Company, Inc.
Footnotes
We have included certain financial measures in this press release, including
those listed below, which are “non-GAAP financial measures” as defined under the
rules and regulations promulgated by the SEC. These non-GAAP financial measures
include, and are defined, as follows:
• EBITDA: net income attributable to Acadia Healthcare Company, Inc. adjusted
for net income attributable to noncontrolling interests, provision for income
taxes, net interest expense and depreciation and amortization.
• Adjusted EBITDA: EBITDA adjusted for equity-based compensation expense,
transaction, legal and other costs, debt extinguishment costs, legal settlements
expense, loss on impairment and gain on sale of property, net.
• Adjusted income before income taxes attributable to Acadia Healthcare Company,
Inc.: net income attributable to Acadia Healthcare Company, Inc. adjusted for
transaction, legal and other costs, debt extinguishment costs, legal settlements
expense, loss on impairment, gain on sale of property, net, and provision for
income taxes.
• Adjusted income attributable to Acadia Healthcare Company, Inc.: Adjusted
income before income taxes attributable to Acadia Healthcare Company, Inc.
adjusted for the income tax effect of adjustments to income.
• Total facility adjusted EBITDA: Adjusted EBITDA adjusted for general and
administrative costs related to our corporate functions. General and
administrative costs directly related to the facilities are included in total
facility results.
• Same facility adjusted EBITDA: Adjusted EBITDA for facilities and services to
those facilities operated in both the current and prior year. These metrics
exclude the operating results associated with facilities under operation for
less than one year and facilities acquired, divested or removed from service
during the current or prior year.
The non-GAAP financial measures presented herein are supplemental measures of
our performance and are not required by, or presented in accordance with,
generally accepted accounting principles in the United States (“GAAP”). The non-
GAAP financial measures presented herein are not measures of our financial
performance under GAAP and should not be considered as alternatives to net
income or any other performance measures derived in accordance with GAAP or as
an alternative to cash flow from operating activities as measures of our
liquidity. Our measurements of these non-GAAP financial measures may not be
comparable to similarly titled measures of other companies. We have included
information concerning the non-GAAP financial measures in this press release
because we believe that such information is used by certain investors as
measures of a company’s historical performance. We believe these measures are
frequently used by securities analysts, investors and other interested parties
in the evaluation of issuers of equity securities, many of which present similar
non-GAAP financial measures when reporting their results. Because the non-GAAP
financial measures are not measurements determined in accordance with GAAP and
are thus susceptible to varying calculations, the non-GAAP financial measures,
as presented, may not be comparable to other similarly titled measures of other
companies. Our presentation of these non-GAAP financial measures should not be
construed as an inference that our future results will be unaffected by unusual
or nonrecurring items.
- MORE -
ACHC Announces Third Quarter 2026 Results
Page 11
November 4, 2026
Total facility results include operating results for all of our facilities and
services but exclude general and administrative costs related to our corporate
functions. Such costs related to our corporate functions include, amongst
others, costs for accounting and finance, information systems, human resources,
legal and operational and executive leadership. General and administrative costs
directly related to the facilities are included in facility results. Such costs
directly related to our facilities include, amongst others, labor at the
facility level, insurance, including property, professional, legal and general
liability insurance, hospital supplies, including medication, utilities and food
service, and general maintenance costs for the facility. We determine which
general and administrative costs to exclude and include in total facility
results by ensuring those costs directly associated with facility operations are
captured at the facility level for reporting. Note that total facility costs
include those related to new facilities and the cost of closure and run-out
costs related to facilities we have closed. We believe that providing results on
a total facility basis is helpful to our investors as a measure of our financial
and operating performance because it neutralizes the impact of corporate-level
items that do not arise out of our core operations at our facilities.
Same facility results include operating results only for facilities and services
operated in both the current and prior year. These metrics exclude the operating
results associated with facilities under operation for less than one year and
facilities acquired during the current or prior year, as well as facilities
divested or removed from service. We believe that providing results on a same
facility basis is helpful to investors because it neutralizes the impact of new
facilities that are in early stages of operation and facilities that we no
longer operate, each of which may distort investors’ understanding of the
Company’s underlying performance at our existing and continuing facilities.
Further, we believe that providing same facility information is helpful to our
investors as a measure of the financial and operating performance of our
existing and continuing facilities on a comparable basis, and same facility
results provide investors with information useful in understanding underlying
organic growth in such facilities. For these reasons, we believe that same
facility results are particularly useful during periods of significant expansion
or contraction.
Total facility results reflect adjustments that are intended to provide the
specific presentation described above, and same facility results reflect
adjustments that may be irregular in timing from period to period related to
newly opened or acquired facilities or facilities that we no longer operate, and
may omit certain results that investors may view as important. Total facility
and same facility results may therefore not be indicative of the overall
performance of our business and should be not be considered as alternatives for
net income or any other performance measures derived in accordance with GAAP.
The Company is not able to provide a reconciliation of projected Adjusted EBITDA
and adjusted earnings per diluted share, where provided, to expected results due
to the unknown effect, timing and potential significance of transaction-related
expenses and the tax effect of such expenses.
- MORE -
ACHC Announces Third Quarter 2026 Results
Page 12
November 4, 2026
Acadia Healthcare Company, Inc.
Footnotes (continued)
(a) Represents the equity-based compensation expense of Acadia. Equity-based
compensation expense is excluded from Adjusted EBITDA because we believe that
the cost of equity awards granted to employees does not contribute to the
earnings potentially available for distributions to Acadia's equity holders or
reinvestment into the Company's business.
(b) Represents transaction, legal, and other costs incurred by Acadia primarily
related to the following categories: (1) government investigations; (2) legal,
accounting, and other acquisition-related costs; (3) termination and
restructuring costs; and (4) management transition costs. Government
investigations include legal fees and settlement costs related to certain
litigation. Legal, accounting and other acquisition-related costs include costs
incurred for the development of new facilities ($0.1 million and $0.5 million
for the three months ended September 30, 2026 and 2025, respectively, and $0.5
million and $1.9 million for the nine months ended September 30, 2026 and 2025,
respectively); and legal and settlement costs incurred related to certain
litigation not included in government investigations ($3.2 million and $0.4
million for the three months ended September 30, 2026 and 2025, respectively,
and $12.9 million and $(2.3) million for the nine months ended September 30,
2026 and 2025, respectively). Termination and restructuring costs include costs,
net of gains, incurred related to workforce reductions, contract amendments, and
the closure and disposition of certain facilities, including related lease
terminations. Management transition costs consist primarily of severance
benefits incurred with the departure of the Company’s former Chief Executive
Officer, Christopher H. Hunter. The table below quantifies each of the
components of transaction, legal and other costs for the periods presented. Such
transaction, legal and other costs are excluded from Adjusted EBITDA because we
believe that the nature, size, and number of these costs can vary dramatically
from period to period and between Acadia and its peers and can also obscure
underlying business trends and make comparisons of long-term performance
difficult.
Three
Mont…
Ended Nine
Sept… Mont…
30, Ended
2026 Sept…
(in 30,
thou… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Gov… $ 18,2… $ 38,7… $ 38,162 $ 123,…
inv…
Leg…
acc…
and 3,374 976 13,414 (304 )
oth…
acq…
cos…
Ter…
and 2,096 3,206 12,842 15,4…
res…
cos…
Man…
tra… — — 3,913 —
cos…
Tra…
leg…
and $ 23,7… $ 42,9… $ 68,331 $ 138,…
oth…
cos…
(c) Represents debt extinguishment costs recorded during the first quarter of
2025 in connection with the refinancing of the prior credit facility. Debt
extinguishment is excluded from Adjusted EBITDA because we believe that this
expense is unrelated to Acadia’s day-to-day business operations and not
indicative of Acadia’s ongoing operating results.
(d) Legal settlements gain for the three months ended September 30, 2026
primarily related to the receipt of insurance proceeds in excess of payment of
attorneys' fees and expenses to plaintiffs' counsel in connection with the
settlement of derivative cases against the Company. Legal settlements expense
for the nine months ended September 30, 2026, relates to costs associated with
the settlement of Sandoval v. Acadia Healthcare Company, Inc., Marin County
Super. Ct. No. CIV1802171,partially offset by the receipt of insurance proceeds
in excess of payment of attorneys' fees and expenses to plaintiffs' counsel in
connection with the settlement of derivative cases against the Company. Legal
settlements expense for the nine months ended September 30, 2025, relates to
costs associated with the Desert Hills litigation. Legal settlements expense is
excluded from Adjusted EBITDA because we believe that this expense is unrelated
to Acadia’s day-to-day business operations and not indicative of Acadia’s
ongoing operating results.
(e) Represents non-cash impairment charges. Non-cash impairment charges are
excluded from Adjusted EBITDA because we believe that these charges are
unrelated to Acadia’s day-to-day business operations and not indicative of
Acadia’s ongoing operating results.
- MORE -
ACHC Announces Third Quarter 2026 Results
Page 13
November 4, 2026
(f) Represents loss (gain) on facility property sales. Net gains from facility
property sales are excluded from Adjusted EBITDA because we believe that these
gains are unrelated to Acadia’s day-to-day business operations and not
indicative of Acadia’s ongoing operating results.
(g) Represents general and administrative costs related to our corporate
functions, including, amongst others, costs for accounting and finance,
information systems, human resources, legal and operational and executive
leadership. We determine which general and administrative costs to exclude and
include in total facility results by ensuring those costs directly associated
with facility operations are captured at the facility level for reporting.
Corporate general and administrative costs are excluded to present Total
Facility Adjusted EBITDA because we believe that providing results on a total
facility basis is helpful to our investors as a measure of the financial and
operating performance of our core operations at our facilities.
(h) Represents the portion of EBITDA for the periods presented attributable to
de novos and acquired facilities in operation for less than one year and
facilities closed during such period. De novos are newly developed facilities
built by Acadia or with a joint venture partner. Such amounts are excluded from
Adjusted EBITDA to present Same Facility Adjusted EBITDA because we believe
providing same facility information is helpful to our investors as a measure of
the financial and operating performance of our existing and continuing
facilities on a comparable basis, and same facility results provide investors
with information useful in understanding underlying organic growth in such
facilities.
(i) Represents the income tax effect of adjustments to income based on tax rates
of 24.8% and 19.8% for the three months ended September 30, 2026 and 2025,
respectively, and 25.9% and 22.8% for the nine months ended September 30, 2026
and 2025, respectively. We believe excluding the income tax effect of
adjustments to income assists investors in understanding the tax provision
associated with those adjustments and the effect on net income.
Investor Contact:
- MORE -